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ABSTRACT
The European Best Practice Guideline group (EBPG) issued
guidelines on the evaluation and selection of kidney donor
and kidney transplant candidates, as well as post-transplant re-
cipient care, in the year 2000 and 2002. The new European
Renal Best Practice board decided in 2009 that these guidelines
needed updating. In order to avoid duplication of efforts with
kidney disease improving global outcomes, which published in
2009 clinical practice guidelines on the post-transplant care of
kidney transplant recipients, we did not address these issues in
the present guidelines.
The guideline was developed following a rigorous methodo-
logical approach: (i) identiﬁcation of clinical questions, (ii)
prioritization of questions, (iii) systematic literature review and
critical appraisal of available evidence and (iv) formulation of re-
commendations and grading according to Grades of Recommen-
dation Assessment, Development, and Evaluation (GRADE). The
strength of each recommendation is rated 1 or 2, with 1 being a
‘We recommend’ statement, and 2 being a ‘We suggest’ statement.
In addition, each statement is assigned an overall grade for the
quality of evidence: A (high), B (moderate), C (low) or D (very
low). The guideline makes recommendations for the evaluation of
the kidney transplant candidate as well as the potential deceased
and living donor, the immunological work-up of kidney donors
and recipients and perioperative recipient care.
All together, the work group issued 112 statements. There
were 51 (45%) recommendations graded ‘1’, 18 (16%) were
graded ‘2’ and 43 (38%) statements were not graded. There were
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0 (0%) recommendations graded ‘1A’, 15 (13%) were ‘1B’, 19
(17%) ‘1C’ and 17 (15%) ‘1D’. None (0%) were graded ‘2A’, 1
(0.9%) was ‘2B’, 8 (7%) were ‘2C’ and 9 (8%) ‘2D’. Limitations of
the evidence, especially the lack of deﬁnitive clinical outcome
trials, are discussed and suggestions are provided for future
research.
We present here the complete recommendations about the
evaluation of the kidney transplant candidate as well as the po-
tential deceased and living donor, the immunological work-up
of kidney donors and recipients and the perioperative recipient
care. We hope that this document will help caregivers to
improve the quality of care they deliver to patients. The full
version with methods, rationale and references is published in
Nephrol Dial Transplant (2013) 28: i1–i71; doi: 10.1093/ndt/
gft218 and can be downloaded freely from http://www.
oxfordjournals.org/our_journals/ndt/era_edta.html.
Keywords: donor evaluation, ERBP, guideline, kidney trans-
plantation, perioperative care, recipient evaluation
INTRODUCTION
Caring for kidney transplant recipients (KTRs) requires spe-
cialized knowledge in areas as varied as nephrology, immun-
ology, pharmacology, endocrinology, infectious disease and
cardiology. In this context of increasing complexity coupled
with an exponential growth in the medical literature, clinical
practice guidelines (CPGs) aim at helping clinicians and
other caregivers to deliver evidence-based medicine and
thereby, to improve patient outcomes. Furthermore, guidelines
also help to expose gaps in our knowledge and thereby suggest
areas where additional research is needed. This guideline was
developed following a rigorous methodological approach: (i)
identiﬁcation and selection of a representative work group,
consisting of experts in transplantation (nephrologists, sur-
geons and immunologists) and guideline methodologists; (ii)
identiﬁcation of clinical questions; (iii) prioritization of ques-
tions; (iv) systematic literature review and critical appraisal
of available evidence; (v) formulation of recommendations
and grading according to GRADE; (vi) comparison to existing
guidelines, when available and (vii) suggestions for future re-
search. The GRADE system allows provision of guidance even
if the evidence base is weak, but makes the quality of the avail-
able evidence transparent and explicit. The strength of each
recommendation is rated 1 or 2, with 1 being a ‘We recom-
mend’ statement implying that most patients should receive
the course of action, and 2 being a ‘We suggest’ statement im-
plying that different choices will be appropriate for different
patients with the suggested course of action being a reasonable
choice. In addition, each statement is assigned an overall grade
for the quality of evidence: A (high), B (moderate), C (low) or
D (very low). Although there are reasons other than quality of
evidence to make a grade 1 or 2 recommendation, in general,
there is a correlation between the quality of overall evidence
and the strength of the recommendation. Even if the evidence
is weak, clinicians still need to make clinical decisions in their
daily practice, and they often ask ‘what do the experts do in
this setting’? Therefore, the European Renal Best Practice
(ERBP) board opted to give guidance, even if evidence was
weak or non-existent, which unfortunately is often the case in
nephrology. The draft guidelines were submitted for review to
selected European experts, all European Renal Association -
European Dialysis and Transplantation Association (ERA-
EDTA) members and reviewers selected by the European Society
of Organ Transplantation and The Transplantation Society.
Where appropriate, changes based on these comments were
made in the ﬁnal document. We felt this is an important step
in the development of guidelines, as it fuelled the base of ex-
pertise that enhanced the overall quality of the guideline. We
owe a special debt of gratitude to all those who took time out
of their busy schedules to share their comments with us. They
have been instrumental in improving the ﬁnal guidelines.
We hope that this document will help caregivers to improve
the quality of care they deliver to patients.
Daniel Abramowicz, Transplantation work group Co-chair
Wim Van Biesen, ERBP advisory board Chairman
Pierre Cochat, Transplantation work group Co-chair
Raymond Vanholder, President of ERA-EDTA
CORE RECOMMENDATIONS
Chapter 1. Evaluation of the kidney transplant candidate
1.1 Should we actively screen for the presence of malignancy
in kidney transplant candidates? Is presence or history of ma-
lignancy a contra-indication to kidney transplantation?
1.1.1. We recommend screening kidney transplant candidates
for cancer according to the recommendations that apply to
the general population. (Ungraded Statement)
1.1.2. We suggest screening kidney transplant candidates for
the presence of kidney cancer by ultrasound. (Ungraded
Statement)
1.1.3. We suggest screening for the presence of urothelial
cancer by urinary cytology and cystoscopy in kidney trans-
plant candidates with an underlying kidney disease asso-
ciated with an increased risk of this type of cancer.
(Ungraded Statement)
1.1.4. We recommend screening HCV and HBV-infected
kidney transplant candidates for the presence of hepatocel-
lular carcinoma according to the EASL-EORTC Clinical
Practice Guideline on the management of hepatocellular
carcinoma. (Ungraded Statement)
1.1.5. We suggest that patients with current or previous cancer
should be discussed with an oncologist and considered on a
case-by-case basis. The following factors should be consid-
ered when determining the appropriate time that wait-
listing should be delayed: (a) the potential for progression
or recurrence of the cancer according to its type, staging
and grade; (b) the age of the patient; (c) the existence of
co-morbidities, in order to deﬁne the appropriate period
of time that wait-listing should be delayed. (Ungraded
Statement)
N
D
T
P
E
R
S
P
E
C
T
IV
E
S
T r a n s p l a n t g u i d e l i n e s 1791
1.2 Under which conditions can HIV-infected patients be
enrolled on the waiting list?
1.2.1. We recommend that HIV per se is not a contra-indica-
tion for kidney transplantation. (1C)
1.2.2. We recommend wait-listing HIV patients only if
(1) they are compliant with treatment, particularly HAART
therapy.
(2) their CD4 + T-cell counts are >200/µL and have been
stable during the previous 3 months.
(3) HIV RNAwas undetectable during the previous 3 months.
(4) no opportunistic infections occurred during the previ-
ous 6 months.
(5) they show no signs compatible with progressive multi-
focal leukoencephalopathy, chronic intestinal cryptospor-
idiosis or lymphoma. (1C)
1.2.3. We suggest that the most appropriate anti-retroviral
therapy should be discussed before transplantation with the
infectious diseases team in order to anticipate potential drug
interactions after transplantation. (Ungraded Statement)
1.3 Is there a role for immunization against herpes varicella
zoster prior to kidney transplantation?
1.3.1. We recommend immunization against varicella-zoster
virus in all paediatric and adult patients negative for anti-
varicella-zoster antibodies, preferably when they are still
waitlisted. (1D)
1.4 Should haemolytic uraemic syndrome (HUS) as under-
lying cause of end-stage kidney disease preclude wait-listing
for transplantation and does it inﬂuence graft and patient
survival post-transplantation?
1.4.1. We recommend that typical, proven shiga-toxin E. coli-
associated haemolytic uraemic syndrome (HUS) is not
contra-indication to transplantation from either deceased or
living donors. (1B)
1.4.2. We suggest considering kidney transplantation as an ac-
ceptable option (i) in kidney transplant candidates with atyp-
ical HUS and a proven membrane cofactor protein (MCP)
mutation, and (ii) in those displaying anti-complement
factor H (CFH) auto-antibodies. (Ungraded Statement)
1.4.3 We suggest that kidney transplantation in patients with
atypical HUS should only be undertaken in centres with ex-
perience in managing this condition and where appropriate
therapeutic interventions are available. (Ungraded Statement)
1.4.4. We do not recommend living donation from a genetical-
ly related donor in patients who are suspected to have atyp-
ical HUS as their underlying kidney disease unless the
responsible mutation has been conclusively excluded in the
donor. (1D)
1.4.5. We recommend evaluating the potential of living dona-
tion from a genetically unrelated donor to a recipient with
atypical HUS on a case-by-case basis. It should only be con-
sidered after appropriate counselling of the recipient and
donor on the risk of disease recurrence in the transplanted
graft. (Ungraded Statement)
1.5 Should focal segmental glomerulosclerosis (FSGS) as
underlying cause of end-stage kidney disease preclude wait-
listing for transplantation and does it inﬂuence graft and
patient survival post-transplantation?
1.5.1. We recommend that primary focal segmental glomeru-
losclerosis per se is not a contra-indication to kidney trans-
plantation from either a living or a deceased donor. (1D)
1.5.2. We recommend informing the recipient and in living do-
nation, the potential donor, about the risk of recurrence of
focal segmental glomerulosclerosis in the graft. (Ungraded
Statement)
1.5.3. We recommend that when a ﬁrst graft has been lost
from recurrent focal segmental glomerulosclerosis, a second
graft from either a deceased or a living donor should only
be transplanted after an individual risk/beneﬁt assessment
and careful counselling of the recipient and potential donor
in the case of living donation. (Ungraded Statement)
1.5.4. We suggest using an updated management protocol in
cases of recurrent focal segmental glomerulosclerosis.
(Ungraded Statement)
1.5.5. We suggest that children with steroid-resistant nephrotic
syndrome undergo appropriate genotyping before wait-listing
them for kidney transplantation. (Ungraded Statement)
1.6 Does pre-transplant alcohol and drug abuse in patients
inﬂuence patient or graft survival?
1.6.1. We recommend that women who drink >40 g and men
who drink >60 g of alcohol per day stop or reduce their
alcohol consumption to below these levels. (1D)
1.6.2. These patients can be waitlisted, but careful surveillance
of the reduction of alcohol consumption should be exerted.
(Ungraded Statement)
1.6.3. We recommend that patients with alcohol ‘dependence’
should not be waitlisted. (Ungraded Statement)
1.6.4. Strategies to stop alcohol consumption should be
offered, according to the WHO Clinical Practice Guideline.
(Ungraded Statement)
1.6.5. We recommend that patients with an on-going addic-
tion to ‘hard drugs’ resulting in non-adherence should not
be waitlisted for transplantation. (1D)
1.7 Does pre-transplant tobacco smoking in patients inﬂu-
ence patient or graft survival?
1.7.1. We recommend that patients stop smoking before trans-
plantation. (1B)
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1.7.2. Smoking cessation programmes should be offered.
(Ungraded Statement)
1.8 Should obesity preclude wait-listing for kidney trans-
plantation and is there a difference in outcomes post-trans-
plantation between those with and without obesity?
1.8.1. We recommend that patients with a body mass index
>30 kg/m2 reduce weight before transplantation. (Ungraded
Statement)
1.9 Should kidney transplantation be delayed in patients
presenting with uncontrolled secondary hyperparathyroid-
ism? Does uncontrolled secondary hyperparathyroidism in
the immediate pre-transplant period have an impact on
transplant outcomes?
1.9.1. We recommend not refusing a cadaveric graft only because
of uncontrolled hyperparathyroidism in the recipient. (1D)
1.9.2. However, for patients on the waiting list, efforts should
be made to comply with existing chronic kidney disease—
metabolic bone disease guidelines, including parathyroi-
dectomy, when indicated. (Ungraded Statement)
1.10 How should screening for potential cardiovascular disease
in the potential recipient be done in a cost-effective way?
1.10.1. We recommend that basic clinical data, physical exam-
ination, resting ECG and chest-X ray are a sufﬁcient stand-
ard work-up in asymptomatic low-risk kidney transplant
candidates. (1C)
1.10.2. We recommend performing a standard exercise toler-
ance test and cardiac ultrasound in asymptomatic high-risk
patients (older age, diabetes, history of cardiovascular
disease). In patients with a true negative test, further cardiac
screening is not indicated. (1C)
1.10.3. We recommend performing further cardiac investigation
for occult coronary artery disease with non-invasive stress
imaging (myocardial perfusion or dobutamine stress echo-
cardiography) in kidney transplant candidates with high risk
and a positive or inconclusive exercise tolerance test. (1C)
1.10.4. We recommend performing coronary angiography in
renal transplant candidates with a positive test for cardiac
ischaemia. Further management should be according to the
current cardiovascular guidelines (Figure 1). (1D)
1.11 When and for which indications should native neph-
rectomy be performed in kidney transplant candidates
awaiting kidney transplantation?
1.11.1. We recommend native nephrectomy before transplant-
ation (unilateral or bilateral) in patients with autosomal poly-
cystic kidney disease (ADPKD) when there are severe, recurrent
symptomatic complications (bleeding, infection, stones). (1C)
1.11.2. We suggest unilateral nephrectomy of asymptomatic
ADPKD kidneys when space for the transplant kidney is
insufﬁcient. (2C)
1.11.3. We do not recommend routine native nephrectomy,
unless in cases of recurrent upper urinary tract infections or
when the underlying kidney disease predisposes to enhanced
cancer risk in the urogenital tract. (Ungraded Statement)
Chapter 2. Immunologic work-up of kidney donors and
recipients
2.1. How should HLA typing be performed in renal trans-
plant candidates and donors?
2.1.1. We suggest that at least one typing is performed by mo-
lecular human leucocyte antigen (HLA) typing of patients
and donors to avoid mistakes in the classiﬁcation of the
HLA antigens. (2D)
2.1.2. We suggest that HLA typing is performed in duplicate,
preferentially on separate samples obtained at different
occasions to avoid logistical errors. (Ungraded Statement)
2.1.3. In case of sensitized patients, we recommend additional
serological typing of the donor cells to be used for cross-
matches in order to check the proper expression of the HLA
antigens on the target cells. (1D)
2.1.4. For highly sensitized patients with allele-speciﬁc anti-
bodies we suggest consideration of high resolution molecu-
lar typing in both recipients and donors. (2D)
2.2. In a renal transplant recipient, how should HLA
matching be used to optimize outcome?
2.2.1. We suggest matching for human leucocyte antigen
(HLA)-A, -B and -DR whenever possible. (2C)
2.2.2. We recommend balancing the effects of HLA matching
with other parameters that affect patient and graft outcomes
when deciding the acceptance of a potential graft. (1D)
2.2.3. We recommend giving preference to an HLA identical
donor and recipient combination. (1B)
2.2.4. We suggest giving more weight to HLA-DR matching
than to HLA A and B matching. (2C)
2.2.5. We recommend giving more weight to HLA matching in
younger patients, in order to avoid broad HLA sensitization
which might impair re-transplantation. (Ungraded Statement)
2.3. In renal transplant candidates, what HLA antigens and
non-HLA antigens should be deﬁned in addition to HLA A,
B and DR?
2.3.1. We recommend performing human leucocyte antigen
(HLA) DQ, HLA DP and HLA C typing of the donor only
when the intended recipient has HLA antibodies against
those antigens. (1D)
2.3.1. We do not recommend routine typing for major histo-
compatibility complex class I related chain-A (MICA) and
other non-HLA antigens in either the recipient or donor.
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2.4. In HLA-sensitized kidney transplant candidates what
measures should be attempted to improve the probability of
a successful transplantation?
2.4.1. We recommend establishing programmes to select a
donor towards whom the recipient does not produce
antibodies. (1C)
2.4.2. In recipients from cadaveric kidney donors, this aim can
be achieved by an acceptable mismatch programme. (1C)
2.4.3. In living donation this goal can be achieved by paired
exchange. (Ungraded Statement)
2.4.4. We recommend transplanting patients with donor-speciﬁc
antibodies only if these abovementioned measures cannot be
accomplished and after successful intervention. (1D)
F IGURE 1 . Decision tree pre-transplant cardiovascular screening.
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2.5. In renal transplant candidates, should a failed allograft
that is still in place be removed or left in place?
2.5.1. Evidence comparing patients with a failed transplant
with versus without nephrectomy is insufﬁcient and con-
ﬂictive, hampering a meaningful general recommendation
on whether or not nephrectomy of failed grafts should be
recommended. (Ungraded Statement)
2.5.2. We suggest that in the following conditions an explant-
ation of the failed kidney graft be considered: clinical rejection,
chronic systemic inﬂammation without other obvious cause
or recurrent (systemic) infections. (Ungraded Statement)
2.5.3. We suggest to continue low-level immunosuppression
and to avoid nephrectomy of a failed graft when residual
graft urinary output is >500 mL/day and there are no signs
of inﬂammation. (Ungraded Statement)
2.6. In renal transplant candidates, what technique of cross-
match should be used to optimize outcomes?
2.6.1. We recommend performing a complement-dependent
cytotoxic (CDC) crossmatch in HLA-sensitized patients to
prevent hyperacute rejection. (1B)
2.6.2. We suggest that in HLA antibody negative patients with
negative regular quarterly screening samples a crossmatch
can be omitted, unless a potential HLA sensitizing event has
occurred since last screening. (2B)
2.6.3. We do not recommend performing a Luminex or endo-
thelial cell crossmatch because their additional value needs
further evaluation. (1D)
2.6.4. We recommend that a positive CDC crossmatch should
only be accepted as truly positive when donor-speciﬁc anti-
bodies are known to be present. (1B)
2.7. In renal transplant candidates planned to undergo
living donor transplantation but for whom the available
donor is ABO incompatible, what measures can be taken to
improve outcome after transplantation?
2.7.1. We recommend both inhibition of antibody production
and ABO antibody removal before transplantation applied
together in one and the same validated protocol. (1C)
2.7.2. We recommend transplantation of an ABO incompat-
ible kidney only if the ABO antibody titre after intervention
is lower than 1:8. (1C)
2.7.3. We suggest considering paired exchange when available.
(Ungraded Statement)
2.8. In previously transplanted patients, what is the effect of
repeated mismatches for HLA antigens on outcome, as com-
pared to avoiding repeated HLA mismatches?
2.8.1. We recommend that repeated human leucocyte antigen
(HLA) mismatches are not considered a contra-indication
for transplantation in the absence of antibodies against
those repeated mismatches. (Ungraded Statement)
2.8.2. We suggest that the presence of antibodies against the
repeated mismatch detectable by other techniques than
the complement-dependent cytotoxic (CDC) technique be
considered as a risk factor rather than a contra-indication.
(Ungraded Statement)
Chapter 3. Evaluation, selection and preparation
of deceased and living kidney donors
3.1. When is dual kidney transplantation preferred over
single kidney transplantation?
3.1.1. We recommend that before the kidneys of a cadaveric
donor are discarded because they are deemed unsuitable for
single transplantation, transplantation of both kidneys into
one recipient (dual kidney transplantation) is considered as
an option. (1C)
3.1.2. We suggest that in cadaveric donors where there is un-
certainty about the quality of the kidneys, the decision to
either discard the kidneys, or use them as a dual or a single
transplant, is based on a combination of the clinical evalu-
ation and history of the recipient and donor, and when
available, a standardized assessment of a pre-transplant
donor biopsy. (2D)
3.1.3. We recommend that before a kidney from a paediatric
donor is discarded due to low donor age it is deemed un-
suitable for single transplantation in an adult recipient, en
bloc transplantation is considered. (1B)
3.1.4. We suggest that the option of using kidneys for en bloc
transplantation is always considered for donors weighing
less than 10 kg. (1D)
3.2. Which perfusion solution is best suited for kidney pres-
ervation in recipients of living donation? Which perfusion
solution is best suited for kidney preservation in recipients
of deceased kidney donation?
3.2.1. There is insufﬁcient evidence to favour a particular pres-
ervation solution for kidneys that carry a low risk of delayed
graft function. (Ungraded Statement)
3.2.2. We recommend not using Eurocollins as a preservation
solution for kidneys that carry a high risk of delayed graft
function (long projected cold ischaemia time, extended cri-
teria donors). (1B)
3.3. Is machine perfusion superior to standard perfusion?
3.3.1. There are conﬂicting data regarding the generalizability
of the beneﬁt of machine perfusion over static cold storage.
Until further evidence emerges, no ﬁrm recommendation
for the use of machine perfusion in preference to cold
storage can be made. (Ungraded Statement)
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3.4. Is there a critical cold ischaemia time beyond which a
donated organ should be discarded?
3.4.1. We suggest that cold ischaemia time be kept as short as
possible. (2D)
3.4.2. We recommend keeping cold ischaemia time below 24
hours when transplanting kidneys from donors after brain
death. (1B)
3.4.3. We recommend keeping cold ischaemia time to less than
12 hours when using kidneys from donors after cardiac
death. (1D)
3.4.4. We recommend that the decision to use donor kidneys
with a cold ischaemia time of more than 36 hours be made
on a case per case basis. (1D)
3.5. On which criteria should we select living kidney donors
to optimize the risk/beneﬁt ratio of their donation?
General remarks
3.5.1. We recommend encouraging living kidney donors to
exercise on a regular basis and when relevant, to lose weight
and stop smoking. (1C)
3.5.2. We recommend that the individual risk of donation
should be carefully discussed with the donor, taking into
account the situation of both donor and recipient. Ideally,
this should be done using standardized checklists to ensure
all items are discussed. (Ungraded Statement)
3.5.3. We suggest that the donor be evaluated by an independ-
ent physician who is not part of the transplant team and is
not involved in the daily care of the recipient, and when
possible, by a psychologist. (Ungraded Statement)
3.5.4. We recommend that the process of donation is stopped
should any doubt on donor safety arise, especially in younger
donors, or when the beneﬁt for the recipient is limited.
(Ungraded Statement)
3.5.5. We recommend that the simultaneous presence of more
than one risk factor (hypertension, obesity, proteinuria, im-
paired glucose tolerance, haematuria) precludes donation.
(Ungraded Statement)
Hypertension
3.5.6. We recommend considering potential donors with a
blood pressure <140/90 mmHg on at least three occasions
without antihypertensive medication, as normotensive. (1C)
3.5.7. We suggest measuring ambulatory blood pressure in po-
tential donors who have ofﬁce hypertension (blood pressure
≥140/90 mmHg) or who are taking pharmacological treat-
ment for hypertension. (2C)
3.5.8. We suggest well-controlled primary hypertension, as as-
sessed by ambulatory blood pressure <130/85 mmHg,
under treatment with maximum two anti-hypertensive drugs
(diuretics included) is not considered a contra-indication to
living kidney donation. (2C)
3.5.9. We recommend declining hypertensive donors with
evidence of target organ damage such as left ventri-
cular hypertrophy, hypertensive retinopathy and micro-
albuminuria. (1C)
3.5.10. We suggest that these potential donors be re-evaluated
for disappearance of this target organ damage after appro-
priate treatment. (2D)
Obesity
3.5.11. We suggest a body mass index above 35 kg/m2 is a
contra-indication to donation. (2C)
3.5.12. We recommend counselling obese and overweight
donors for weight loss before and after donation. (Ungraded
statement)
Impaired glucose tolerance
3.5.13. We recommend diabetes mellitus is a contra-indication
to donation, other than in exceptional circumstances. (1D)
3.5.14. We suggest impaired glucose tolerance is not an abso-
lute contra-indication to donation. (2C)
Proteinuria
3.5.15. We recommend to quantify urinary protein excretion
in all potential living donors. (1C)
3.5.16. We recommend overt proteinuria is a contra-indication
for living donation [24-hour total protein >300 mg or spot
urinary albumin to creatinine (mg/g) ratio >300 (>30 mg/
mmoL)]. (1C)
3.5.17. We recommend further evaluating potential living
donors with persistent (more than three measurements
with 3 months interval) proteinuria <300 mg/24 h by quan-
tiﬁcation of albuminuria to assess their risk of living dona-
tion. (Ungraded statement)
3.5.18. We suggest considering persistent (more than three
measurements with 3 months interval) moderate albumin-
uria (30–300 mg/24 h) a high risk for donation. (Ungraded
statement)
Haematuria
3.5.19. We recommend considering persistent haematuria of
glomerular origin as a contra-indication to living donation,
because it may indicate renal disease in the donor. (1B)
3.5.20. However, we acknowledge thin basement membrane
disease might be an exception. (Ungraded statement)
Old age
3.5.21. We recommend that old age in itself is not a contra-in-
dication to donation. (1B)
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3.6. What lower level of kidney function precludes living
donation?
3.6.1. We recommend that all potential living kidney donors
should have their glomerular ﬁltration rate (GFR) assessed. (1C)
3.6.2. We recommend that in cases where more exact knowledge
on GFR is needed or where is doubt regarding the accuracy of
GFR from estimation methods, a direct measurement of GFR
should be undertaken by exogenous clearance methods.
(Ungraded Statement)
3.6.3. We recommend that all potential donors should have a
predicted GFR that is projected to remain above a satisfac-
tory level after donation within the life-time of the donor as
indicated in the graph below. (Ungraded Statement)
3.7. What are the risks of pregnancy in a woman with a
single kidney after living kidney donation?
3.7.1. We recommend informing women of childbearing age
that as they are a selected from a very healthy subpopulation,
donation increases their individual risk from below that of the
general population, to that of the general population. (1B)
3.8. What is the best surgical approach for living donor
nephrectomy for the donor? What is the best surgical
approach for living donor nephrectomy for the recipient?
3.8.1. For living donor nephrectomy we suggest either a min-
imally invasive or laparoscopic approach rather than a ﬂank
subcostal retroperitoneal one. The choice between minimal
invasive and laparoscopic procedure should be based on the
local expertise. (2C)
Chapter 4. Perioperative care of the kidney transplant
recipient
4.1. What are the indications for an additional haemodialy-
sis session in the recipient immediately before the trans-
plantation procedure?
4.1.1. We recommend not routinely performing a haemodialy-
sis session immediately before the actual transplantation
procedure unless there are speciﬁc clinical indications. (1C)
4.1.2. When additional haemodialysis is performed immedi-
ately before the transplantation procedure, we recommend
not using ultraﬁltration unless there is evidence of ﬂuid
overload. (1C)
4.2. Does the use of central venous pressure measurement as
a guidance tool for ﬂuid management in kidney transplant
recipients improve the outcome after transplantation?
4.2.1. We suggest that central venous pressure be measured
and corrected in the early post-operative period to prevent
hypovolemia and delayed graft function. (2D)
4.3. In kidney transplant recipients during the perioperative
period, does the use of intravenous solutions other than 0.9%
sodium chloride improve patient and/or graft outcome?
4.3.1. There is no evidence to prefer one type of solution (crys-
talloids versus colloids, normal saline versus Ringer) for
intravenous volume management of the recipient during
kidney transplant surgery.
4.3.2. In view of the available data in the literature, and in line
with the ERBP position on prevention of AKI, we suggest to
be cautious with the use of starches in the kidney transplant
recipient during the perioperative period, although speciﬁc
data in this setting are lacking. (Ungraded Statement)
4.3.3. We recommend monitoring for metabolic acidosis when
normal saline is used as the only intravenous ﬂuid in the
perioperative and post-operative period. (1B)
4.4. Does the use of dopaminergic agents (dopamine and its
alternatives) improve early post-operative graft function?
4.4.1. We do not recommend the use of ‘renal doses’ of dopa-
minergic agents in the early post-operative period, since it
does not improve graft function or survival. (1B)
4.5. Should we use prophylactic antithrombotic agents
during the perioperative period?
4.5.1. We do not recommend routinely using low-molecular-
weight heparin, unfractionated heparin or aspirin before
transplantation to prevent graft thrombosis. (1B)
4.6. In renal transplant recipients, what are the effects of
using a JJ stent at the time of operation on renal outcomes?
4.6.1. We recommend prophylactic JJ stent placement as a
routine surgical practice in adult kidney transplantation.
(1B)
4.6.2. We suggest that if a JJ stent is in place, cotrimoxazole is
given as antibiotic prophylaxis. (2D)
4.6.3. We suggest removing the JJ stent within 4–6 weeks.
(Ungraded Statement)
4.7. What is the optimal post-operative time for removal of the
indwelling bladder catheter in kidney transplant recipients?
4.7.1. We suggest removing the urinary bladder catheter as
soon as possible after transplantation, balancing the risk of
urinary leak against that of urinary tract infection. (2D)
4.7.2.We recommendmonitoring adverse event rates (urinary tract
infection, urinary leakage) in each centre, to inform the decision
over when to remove the indwelling bladder catheter. (1D)
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